Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Telithromycin

FDA-approved product (tablet, oral), marketed as Ketek.

Registered studies
26
Lab records
11
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Telithromycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Bacterial pneumonia
  • Chronic bronchitis
  • Community-Acquired Infections
  • Infection
  • Pharyngitis
  • Pneumonia
  • Recurrent tonsillitis
  • Sinusitis
  • Tonsillitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Macrolides
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01FA15

Repurposing investigation

Telithromycin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli73.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae44.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

26registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 9 of 11 lab records
Open Telithromycin in ChEMBL Registered studies below
Show the 11 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Telithromycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • KEYS: Study Comparing Clinical Health Outcomes of Telithromycin Versus Azithromycin in Outpatients With Community-acquired Lower Respiratory Tract Infections

    NCT00132951 · start 2004-10

    Registered record
    Registry ID
    NCT00132951
    Conditions
    Respiratory Tract Infections; Chronic Bronchitis; Pneumonia
    Interventions
    Telithromycin; Azithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2004-10
    Completion
    2006-09
    Enrolment
    2,051

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRespiratory Tract Infections; Chronic Bronchitis; Pneumonia
    InterventionTelithromycin; Azithromycin
    PhasePhase 4
    Registry statusTerminated

  • Japanese Study Evaluating Safety, Efficacy and Acceptability of Telithromycin in Children With Infections

    NCT00408135 · start 2004-08

    Registered record
    Registry ID
    NCT00408135
    Conditions
    Infections; Child
    Interventions
    telithromycin (HMR3647)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-08
    Completion
    2005-05
    Enrolment
    111

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections; Child
    Interventiontelithromycin (HMR3647)
    PhasePhase 3
    Registry statusCompleted

  • Ketek in CAP / AECB in Ambulatory Adult Patients

    NCT00546676 · start 2004-05

    Registered record
    Registry ID
    NCT00546676
    Conditions
    Community Acquired Pneumonia (CAP); Acute Exacerbation of Chronic Bronchitis (AECB)
    Interventions
    Telithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-05
    Completion
    2004-12
    Enrolment
    174

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCommunity Acquired Pneumonia (CAP); Acute Exacerbation of Chronic Bronchitis (AECB)
    InterventionTelithromycin
    PhasePhase 4
    Registry statusCompleted

  • Japanese Study Evaluating the Effects of Telithromycin in Children With Community-Acquired Pneumonia

    NCT00638859 · start 2004-03

    Registered record
    Registry ID
    NCT00638859
    Conditions
    Pneumonia
    Interventions
    Telithromycin (HMR3647)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-03
    Completion
    2004-10
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia
    InterventionTelithromycin (HMR3647)
    PhasePhase 3
    Registry statusCompleted

  • Japanese Study Evaluating the Effects of Telithromycin in Children With Acute Otitis Media

    NCT00638534 · start 2004-02

    Registered record
    Registry ID
    NCT00638534
    Conditions
    Otitis Media
    Interventions
    Telithromycin (HMR3647)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-02
    Completion
    2004-10
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOtitis Media
    InterventionTelithromycin (HMR3647)
    PhasePhase 3
    Registry statusCompleted

  • PERSPECTIVE: Telithromycin - Acute Exacerbation of Chronic Bronchitis

    NCT00132938 · start 2004-01

    Registered record
    Registry ID
    NCT00132938
    Conditions
    Chronic Bronchitis
    Interventions
    telithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-01
    Completion
    2006-05
    Enrolment
    5,660

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Bronchitis
    Interventiontelithromycin
    PhasePhase 4
    Registry statusCompleted

  • TELICAST : Telithromycin in Acute Exacerbations of Asthma

    NCT00273520 · start 2003-01

    Registered record
    Registry ID
    NCT00273520
    Conditions
    Asthma
    Interventions
    Telithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-01
    Completion
    2004-05
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionTelithromycin
    PhasePhase 3
    Registry statusCompleted

  • Telithromycin, Treating Adult Outpatients With Mild to Moderate Community-acquired Pneumonia (CAP) in High Bacterial Resistance Areas

    NCT00538018 · start 2003-01

    Registered record
    Registry ID
    NCT00538018
    Conditions
    Pneumonia
    Interventions
    Telithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-01
    Completion
    2004-06
    Enrolment
    978

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia
    InterventionTelithromycin
    PhasePhase 4
    Registry statusCompleted

  • AMS VS MOXI Ketek vs Avelox in AMS

    NCT00537563 · start 2002-12

    Registered record
    Registry ID
    NCT00537563
    Conditions
    Maxillary Sinusitis
    Interventions
    Telithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-12
    Completion
    2003-09
    Enrolment
    351

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMaxillary Sinusitis
    InterventionTelithromycin
    PhasePhase 3
    Registry statusCompleted

  • Telithromycin: in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adult Outpatients With COPD

    NCT00538148 · start 2002-11

    Registered record
    Registry ID
    NCT00538148
    Conditions
    Bronchitis, Chronic
    Interventions
    Telithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-11
    Completion
    2004-09
    Enrolment
    668

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBronchitis, Chronic
    InterventionTelithromycin
    PhasePhase 4
    Registry statusCompleted

  • Risk of Acute Liver Injury in Users of Antimicrobials

    NCT01434173 · start 2001-07

    Registered record
    Registry ID
    NCT01434173
    Conditions
    Drug-Induced Liver Injury
    Interventions
    Moxifloxacin (Avelox, BAY12-8039); Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2001-07
    Completion
    2009-03
    Enrolment
    1,299,056

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug-Induced Liver Injury
    InterventionMoxifloxacin (Avelox, BAY12-8039); Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
    PhaseNot recorded
    Registry statusCompleted